Novo Nordisk Announces New Drug Pipeline Amid Investor Skepticism
On September 21, Novo Nordisk CEO Mike Doustdar outlined a plan to launch several new blockbuster drugs over the next few years during an investor day in London. Despite these promises, investors remained skeptical and sent shares down roughly 8%. The company's revenue is expected to grow at a pace similar to other large drugmakers through the end of this decade, but concerns persist about what will happen when Ozempic and Wegovy—two-thirds of Novo’s sales last year—lose patent protection in the U.S. by 2032. Doustdar emphasized that lower prices due to patent expirations could drive higher demand in some markets, citing examples like Canada and India where semaglutide is already off-patent. However, investors were not reassured, with analysts noting limited differentiation in Novo’s pipeline compared to competitors such as Eli Lilly. The company aims for over 150 billion Danish kroner ($23 billion) in sales from its new drugs by 2035—seen as conservative and somewhat disappointing. Novo is competing fiercely with Eli Lilly, which has a strong presence in the weight-loss drug market through Mounjaro and Zepbound. While Novo’s Wegovy pill has had a successful launch, analysts remain unconvinced about its long-term growth strategy.
Topics: blockbuster drugs investor reaction Novo Nordisk Ozempic Wegovy